key: cord-0072530-zz8f4ay0
authors: Lombardozzi, G.; Matrone, M.; Amici, E.; Trovini, G.; Perrini, F.; Giovanni, A. Di; Giovanetti, V.; Kotzalidis, G.D.; De Filippis, S.
title: P.0669 Differential response to three antidepressants in patients with major depressive episode who suffered Covid-19–related trauma
date: 2021-12-30
journal: Eur Neuropsychopharmacol
DOI: 10.1016/j.euroneuro.2021.10.631
sha: fa7cfeb991a38d3e6780c91fae879989f022f9b4
doc_id: 72530
cord_uid: zz8f4ay0

nan

G. Lombardozzi, M. Matrone, E. Amici et al.

from the kit according to injection site and body habitus. Though the bioavailability of deltoid vs. gluteal sites is generally considered equivalent [3] , the pK parameters are different depending on injection site, and further influenced by dose (and volume); deltoid vs. gluteal IM injections are generally associated with a shorter T max , greater C max , and a shorter T 1/2 . These pK differences result in a differential drug exposure with potential effects on clinical response and tolerability, depending on the injection site [4] . For mental health clients the use of deltoid injections is associated with less stigma, greater convenience and greater practicality in multiple, clinical scenarios [5] . However, current Canadian nursing practice recommends IM injection in the ventrogluteal muscle as the preferred route for irritating, viscous and larger volumes; and to consider IM injections only in a well-developed deltoid muscle and volumes of less than 2mL. Conclusion: The advantages and disadvantages of deltoid vs. gluteal IM injections of LAIs should be considered in the context of nursing best practice and real world practicality. For mental health clients the injection site plays a role in patient acceptance and ease of use. A knowledge of how injection site affects pK is important in achieving optimal efficacy and tolerability.

Disclosure statement: I have received educational, research and travel grants and honoraria from Lundbeck, Boehringer Ingelheim, Diamentis, Alkermes, AbbVie, HLS, Janssen, Mylan, Pfizer and Otsuka. Introduction . The Covid 19 has probably altered the epidemiology of mental disorders worldwide, with their incidence which is likely to have increased during the pandemic [ 1 , 2 ] . It is possible that it has impacted response to drug treatment in psychiatric conditions, resulting in differential hospitalisation rates. Hence, we compared the responses to three different antidepressant drugs in outpatients with a major depressive episode (MDE) in the course of Major Depressive Disorder (MDD) and Bipolar Disorder (BD) during two time periods, i.e., prior to suffering Covid-19-related trauma and after suffering such trauma. Methods . We conducted an observational study on outpatients with MDE during their course of MDD (N = 58) or BD (N = 84)who were clinically stabilised for at least 6 months and treated with antidepressants, antipsychotics or mood stabilisers according to recent treatment guidelines [ 3 , 4 ] . 

Our main findings suggest that OC trigger a specific FEP phenotype characterized by earlier and more protracted onset of illness and higher burden of symptoms, which is independent from the type of first episode (i.e. affective and non-affective). These results indicate a potential target of early intervention in FEP.

Anxiety and depression among general population in China at the peak of the COVID-19 epidemic

Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia

The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders

Germanes Hospitalàries Research Foundation

Birth weight and obstetric compli